da Vinci 5 System Installed Base Tops 1,700
As of June 30, 2026, the installed base of da Vinci 5 systems reached 1,710, with 136 located outside the U.S., reflecting strong customer adoption since its 2024 launch.
At the archive date, INTUITIVE SURGICAL INC was expected to release its Q3 2026 10-Q filing on October 19, 2026, after market close. Last quarter: Intuitive Surgical delivered robust Q2 FY2026 results, with double-digit revenue and earnings growth propelled by da Vinci 5 adoption and higher procedure volumes, while navigating tariff and regulatory challenges.
EPS Estimate
$2.69
Revenue Estimate
$2.96B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the ISRG page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
As of June 30, 2026, the installed base of da Vinci 5 systems reached 1,710, with 136 located outside the U.S., reflecting strong customer adoption since its 2024 launch.
The Company recognized $35.9 million in refunds for previously paid IEEPA tariffs, which reduced cost of revenue and contributed to the gross margin expansion in the quarter.
Recent FDA approvals included da Vinci 5 for cardiac procedures, extended-use force feedback instruments, and da Vinci SP for multiple general surgery indications, broadening the clinical utility of Intuitive’s platforms.
Revenue
$2.89B
+18.54% YoY
EPS (Diluted)
$2.29
+26.52% YoY
Gross Margin
67.8%
+1.5 pts YoY
Operating Income
$971.9M
+30.74% YoY
Add ISRG to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.